CClinicalTrials.gg
CompletedNCT01468662Updated Oct 28, 2014

CMR Repeatability in STEMI

An observational study in STEMI, sponsored by University of Bristol. Completed at 1 site in United Kingdom. Open to female participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2014-10-28.

Sponsored by University of Bristol · Observational

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
40
Ages
18 Years to 85 Years
Sex
Female
01

Study summary

The investigators propose to conduct a study to measure the reproducibility of CMR parameters that have been used to predict outcome following PPCI: infarct size, left ventricular volumes, myocardial salvage, microvascular obstruction (MVO) and myocardial oedema.

02

Conditions studied

03

In context

ST Elevation Myocardial Infarction

667 studies on the registry are indexed under ST Elevation Myocardial Infarction; 180 are open to participants now.

This study's enrollment of 40 is below the median of 329 across 222 observational studies indexed under ST Elevation Myocardial Infarction.

Browse ST Elevation Myocardial Infarction studies →

Lead sponsor

University of Bristol is the lead sponsor of 22 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

ST segment elevation myocardial infarction

Inclusion criteria

Participant may enter study if ALL of the following apply

  1. ST segment myocardial infarction as defined by ECG (by 2 contiguous limb leads with >1 mm ST-segment elevation, or >2 mm ST-segment elevation in contiguous precordial leads, or new LBBB) and > 20 minutes of cardiac chest pain
  2. Written informed consent

Exclusion criteria

Exclusion Criteria:

Participant may not enter study if ANY of the following apply

  1. Contraindication to MRI (implanted pacemaker/ defibrillator, ferromagnetic metal implant/ injury, claustrophobia, obesity/ too large for CMR scanner)
  2. Known allergy to gadolinium
  3. Chronic atrial fibrillation
  4. Renal impairment with eGFR \<30
  5. Cardiogenic shock
  6. Patients with special communication needs
05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
40 participants (actual)

Groups and cohorts

  • STEMI
06

What researchers measure

Primary outcomes

  1. Inter-observer, intra-observer and inter-scan variability and agreement

    Time frame: Between 2 scans

07

Study locations

1 site
  • Bristol Heart Institute
    Bristol, BS2 8HW, United Kingdom
08

References and documents

Publications

  • McAlindon EJ, Pufulete M, Harris JM, Lawton CB, Moon JC, Manghat N, Hamilton MC, Weale PJ, Bucciarelli-Ducci C. Measurement of myocardium at risk with cardiovascular MR: comparison of techniques for edema imaging. Radiology. 2015 Apr;275(1):61-70. doi: 10.1148/radiol.14131980. Epub 2014 Oct 21. PubMed 25333474 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 28, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01468662
Lead sponsor
University of Bristol
Responsible party
Elisa McAlindon (Cardiology Clinical Research Fellow, University of Bristol) — Principal investigator
First posted
Nov 9, 2011
Start date
Nov 2011
Primary completion
Apr 2013
Last update
Oct 28, 2014

Study contacts

Elisa McAlindon, BMBS
principal investigator · University of Bristol

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion